Codiak’s Versatile engEx™ Platform for Engineered Exosomes Published in the Journal Molecular Therapy
January 21, 2021 09:00 ET
|
Codiak BioSciences, Inc.
– New publication details the characterization of novel scaffold proteins that can enable engineered exosomes with defined therapeutic properties – – engEx Platform designed to harness exosomes as a...
Codiak Reports Positive Initial Phase 1 Results for exoIL-12™ Demonstrating Tolerability and Absence of Systemic IL-12 Exposure in Healthy Volunteers
December 30, 2020 07:00 ET
|
Codiak BioSciences, Inc.
– exoIL-12 resulted in no local or systemic treatment-related adverse events – – Local administration of exoIL-12 demonstrated no systemic exposure to IL-12 – – Dose selection data and advancement...
New Publication in Molecular Cancer Therapeutics Highlights Data from Preclinical Development of exoIL-12™ for the Treatment of Cancer
December 21, 2020 09:00 ET
|
Codiak BioSciences, Inc.
– exoIL-12 has demonstrated tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Novel engineered exosome therapeutic...
Codiak BioSciences to Present at the Evercore ISI 3rd Annual HealthCONx Conference
November 23, 2020 07:30 ET
|
Codiak BioSciences, Inc.
CAMBRIDGE, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (NASDAQ: CDAK), a clinical-stage company focused on pioneering the development of exosome-based therapeutics as a new...
Codiak BioSciences Reports Third Quarter 2020 Financial Results and Operational Progress
November 19, 2020 16:05 ET
|
Codiak BioSciences, Inc.
– Human clinical testing now underway with Codiak’s first two candidates, exoIL-12™ and exoSTING™ – – Initial safety results and preliminary systemic exposure/pharmacokinetics of exoIL-12 in healthy...
Codiak Presents Preclinical Data at SITC 2020 Demonstrating Potential of engEx™ Engineered Exosomes to Stimulate Targeted, Integrated Anti-Tumor Immunity
November 09, 2020 08:00 ET
|
Codiak BioSciences, Inc.
– exoIL-12™ demonstrates tissue-retained pharmacology, enhanced anti-tumor activity, potent M1 myeloid recruitment, and superior T cell responses in vivo – – Engineered exosomes with directed...